Abstract CT005: AEGEAN: A phase 3 trial of neoadjuvant durvalumab + chemotherapy followed by adjuvant durvalumab in patients with resectable NSCLC
Work
Year: 2023
Type: article
Source: Cancer Research
Authors John V. Heymach, David H. Harpole, Tetsuya Mitsudomi, Janis M. Taube, Gabriella Gálffy +14 more
Institutions The University of Texas MD Anderson Cancer Center, Duke University Hospital, Duke Medical Center, Kindai University, Sidney Kimmel Cancer Center +13 more
Cites:
Cited by: 74
Related to: 10
FWCI: 22.7
Citation percentile (by year/subfield): 100
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Sustainable Development Goal Good health and well-being
Open Access status: closed